Anticancer medication and risk of blood clots in hospitalised cancer patients with COVID-19
In this study, nearly 5,000 hospitalised cancer patients who were [...]
Delayed nephrectomy after immunotherapy for metastatic kidney cancer
Neoadjuvant therapy is the treatment given as a first step [...]
Outcomes of patients who stopped immunotherapy due to immune-related side effects
Immunotherapy has changed the way advanced renal cell carcinoma (RCC) [...]
Immunotherapy combinations in the first-line treatment of metastatic sarcomatoid kidney cancer
A recent study looked at the efficacy and safety of [...]
PARP1 as a potential biomarker for response to immunotherapy
In a recent study, the researchers looked at the RNA [...]
SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland
The Scottish Medicines Consortium (SMC) has approved the use of [...]
Outcomes and side effects after first-line treatment with combination therapies for kidney cancer
This report looked at the results from 4 studies comparing [...]
ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer
Non-clear cell RCC is about 20-25% of all RCC diagnoses [...]
ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer
KEYNOTE-427 is an open-label, single-arm, phase II study to look [...]
Camrelizumab plus famitinib in patients with advanced or metastatic kidney cancer
An ongoing phase 2 study of a combination of two [...]
